ArticleJournal of nanobiotechnology2025
Bletilla striata polysaccharide microneedles with astragaloside Ⅳ loaded ZIF-8 nanoparticles for wound healing and anti-scar treatment.
Article in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Review
- Hydrogel microneedles functioning in pathological surroundings: where soft materials overcome hard scars.Materials today. Bio · 2026Review
- Approaching Scarless Wound Healing: From Passive Anti-Fibrotic to Proactive and Programmable Pro-Regenerative Strategies.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- 3D printed HAMA/GelMA/lignosulfonate hydrogel integrating oxygen-releasing and antioxidative modules for liver regeneration.Journal of nanobiotechnology · 2026Article
- Garlic-derived exosome-like nanovesicle core-shell platform for sequential infection treatment and tissue repair.Journal of nanobiotechnology · 2026Article
- Herbal polysaccharides-a rising star in engineering multifunctional biomaterials for tissue repair and regeneration.Regenerative biomaterials · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Pathological scars (PS) represent a common complication arising post wound healing, potentially resulting in disfigurement and impaired skin functionality in severe instances. Addressing the clinical challenge wherein conventional single treatment modalities struggle to concurrently expedite wound healing and accurately impede scar formation, this study designed and prepared a pH-responsive Bletilla striata polysaccharide (BSP) microneedle patch (BSP-As@ZIF-8 MNs) using a PDMS mold. This MNs with astragaloside Ⅳ (As) encapsulated in zeolite imidazolate framework (ZIF-8) can intelligently respond to pH variations at different stages of wound healing to enable controlled release of As. When further combined with BSP, they achieve precise synergistic therapy for wound healing and scar inhibition. Furthermore, a thorough and systematic characterization and performance assessment of the MNs were conducted, followed by an evaluation of their efficacy in enhancing wound healing and suppressing scarring using a rat model with full-thickness skin defects and a rabbit ear scar model. The experimental results showed that the BSP-As@ZIF-8 MNs exhibited favorable mechanical properties and skin penetration capabilities, alongside remarkable antibacterial efficacy and satisfactory biosafety profiles. Drug release kinetics indicated that the BSP-As@ZIF-8 MNs released 76.35% of the payload at pH 5.5 and 25.78% at pH 7.4 after 48 h, highlighting an accelerated release of As with decreasing pH levels. Further in vivo experiments demonstrated that the closure rate of BSP-As@ZIF-8 MNs reached 96.85 ± 0.9% on day 14 (p < 0.001), with nearly complete wound healing by day 21, suggesting a mechanism involving the activation of VEGF and inhibition of TNF-α, leading to expedited wound closure. Notably, BSP-As@ZIF-8 MNs prevented scar formation (minimal hypertrophic scarring observed on day 35) by reducing TGF-β1, reducing the type I/III collagen ratio, and regulating collagen deposition within the TGF-β1/Smads pathway. In conclusion, BSP-As@ZIF-8 MNs can synergistically promote wound healing and mitigating scar formation, providing a promising drug delivery strategy for wound repair and scar prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.